-
GlycoMimetics Inc (NASDAQ: GLYC) shares jumped
67.6 percent to $9.00 as the company reported that GMI-1271 has received the FDA Breakthrough therapy designation for adult
relapsed/refractory acute myeloid leukemia.
-
athenahealth, Inc (NASDAQ: ATHN) shares surged 16
percent to $123.30 following a 13D filing from Elliott Associates showing a 9.2 percent stake in the company.
-
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
shares gained 14 percent to $4.31. Leerink Swann upgraded Achillion Pharmaceuticals from Market Perform to Outperform.
-
CytRx Corporation (NASDAQ: CYTR) rose 12.1
percent to $ 0.508. CytRx will present global Phase 3 aldoxorubicin clinical data in patients with soft tissue sarcomas at the
2017 ASCO Annual Meeting.
-
ImmunoGen, Inc. (NASDAQ: IMGN) shares climbed
11.4 percent to $5.27 as the company disclosed promising new clinical data with mirvetuximab soravtansine in ovarian cancer.
-
Veritiv Corp (NYSE: VRTV) gained 9.2 percent to
$43.62. Wells Fargo upgraded Veritiv from Market Perform to Outperform.
-
Perry Ellis International, Inc. (NASDAQ: PERY)
rose 8.5 percent to $19.66 after the company reported stronger-than-expected Q1 results.
-
Incyte Corporation (NASDAQ: INCY) gained 7.9
percent to $130.02 Incyte disclosed that its IDO1 enzyme inhibitor in combo with Merck's anti-PD-1 therapy is 'well-tolerated
and demonstrated durable clinical responses across multiple solid tumors'. The company also announced that first data from
combo of epacadostat with Bristol-Myers' opdivo showed that combo is 'well-tolerated and demonstrates promising clinical
outcomes in multiple advanced solid tumors.'
-
Pandora Media Inc (NYSE: P) rose 5.3 percent to $9.41.
Sirius XM Holdings Inc. (NASDAQ: SIRI) is in
talks about bidding for Pandora, according to sources as reported by the New York Post.
-
L Brands Inc (NYSE: LB) gained 5 percent to $50.80
after the company reported upbeat earnings for its first quarter and raised its FY17 outlook.
-
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares
gained 5 percent to $14.26 after surging 44.62 percent on Wednesday. Syndax issued results from Phase 2 ENCORE 601 trial of
entinostat in combo with Merck's KEYTRUDA for the treatment of advanced melanoma.
-
Teladoc Inc (NYSE: TDOC) shares surged 4.9 percent
to $28.90. KeyBanc initiated coverage of Teladoc with an Overweight rating.
-
Shire PLC (ADR) (NASDAQ: SHPG) shares rose 4
percent to $189.50 after the company disclosed that its lanadelumab study met primary endpoint.
-
Affimed NV (NASDAQ: AFMD) shares rose 3.4 percent
to $2.33. Affimed reported that it will present immune cell engager data at the American Society of Clinical Oncology Annual
Meeting and EACR-AACR-SIC Special Conference.
-
Childrens Place Inc (NASDAQ: PLCE) rose 2.6
percent to $114.50 after the company posted upbeat quarterly profit.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.